EMD SERONO INC
BiotechEMD SERONO INC is a biotechnology company focused on Oncology, Neurology, Immunology. Key products include BAVENCIO.
FDA Novel Drug Designations
(2017-2021)EMD SERONO INC at a Glance
- Growing R&D activity with 13 trials in last 2 years
- Fast trial execution (34 months median completion)
EMD SERONO INC's Key Drugs
EMD SERONO INC's core commercial portfolio centers on BAVENCIO, MAVENCLAD, TEPMETKO, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
Metastatic Merkel cell carcinoma in adults and pediatric patients 12 years and older
Multiple Sclerosis
Metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
EMD SERONO INC's Recent FDA Approvals
New NDA/BLA approvals for EMD SERONO INC over the last two years — novel drugs only, excluding generics and label supplements.
EMD SERONO INC's Therapeutic Areas
EMD SERONO INC's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 5 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EMD SERONO INC's Top Competitors
EMD SERONO INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EMD SERONO INC Pipeline Snapshot
EMD SERONO INC has 112 active clinical programs from ClinicalTrials.gov — 22 Phase 3, 34 Phase 2 and 56 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 8/16 completed
- • Speed: 34 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges